Share
When you hear the words Alzheimer's disease, what do you think of? The truth is, the picture most of us have of the disease is incomplete. Alzheimer's disease doesn't start when someone starts to lose their memory. It actually starts years – sometimes decades – earlier. The Rethinking Alzheimer's Disease Podcast is an engaging, narrative-style podcast miniseries for those curious or motivated to learn about Alzheimer’s disease. Perhaps you have a family member with Alzheimer’s disease, or ca ...
…
continue reading
Manage episode 401930938 series 3448744
Content provided by NYU Langone Health Department of Psychiatry. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by NYU Langone Health Department of Psychiatry or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.
Dr. Christopher Pittenger is a Professor of Psychiatry at the Yale School of Medicine and Director of the Yale OCD Research Clinic. In this episode, he discusses the neurobiology, symptomology, and treatment of Obsessive-Compulsive Disorder (OCD), including potential new treatments such as psychedelics, neurofeedback, glutamate modulators, and transcranial magnetic stimulation (TMS).
00:00 Introduction
00:41 Why is OCD Underdiagnosed?
02:19 Impact of OCD on Individuals
03:40 Taboo Nature of OCD Thoughts
06:10 Biomarkers
08:06 Neurobiology
14:20 Serotonin
16:48 Heterogeneity of OCD
24:00 Glutamate Modulators
29:33 Ketamine
33:13 Psilocybin
38:23 Neurofeedback
44:01 Transcranial Magnetic Stimulation (TMS)
47:22 Relationship Between Depression and OCD
50:24 Future of OCD Treatment
Visit our website for more Insights on Psychiatry.
Watch this episode on YouTube
Executive Producer: Jon Earle
33 episodes
))
